Rhythm Pharmaceuticals (RYTM) Amortization of Deferred Charges (2023 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Amortization of Deferred Charges of $4.6 million for Q1 2026, down 15.37% year-over-year from $5.4 million in Q1 2025, and down 0.84% quarter-over-quarter from $4.6 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Amortization of Deferred Charges for 4 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 15.37% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $19.8 million (down 10.22% YoY), while the FY2025 annual figure was $20.6 million, changed 0.09% from the prior year.
- Amortization of Deferred Charges declined to $4.6 million in Q1 2026 per RYTM's latest filing, from $4.6 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $5.9 million in Q2 2024 and bottomed at $3.1 million in Q3 2023.
- Historically, Amortization of Deferred Charges has averaged $4.8 million across 4 years, with a median of $4.7 million in 2025.
- Annual changes were most pronounced in 2024 — Amortization of Deferred Charges jumped 66.52% — and 2026, when it retreated 15.37%.
- Rhythm Pharmaceuticals' Amortization of Deferred Charges stood at $4.0 million in 2023, then surged by 35.56% to $5.4 million in 2024, then fell by 15.26% to $4.6 million in 2025, then declined by 0.84% to $4.6 million in 2026.
- Business Quant data shows RYTM's Amortization of Deferred Charges at $4.6 million in Q1 2026, $4.6 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.54 Mn |
| Jun 30, 2026 | 4.54 Mn |
| Mar 31, 2026 | 4.58 Mn |
| Mar 31, 2026 | 4.58 Mn |
| Dec 31, 2025 | 4.62 Mn |
| Dec 31, 2025 | 4.62 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Sep 30, 2025 | 4.74 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Jun 30, 2025 | 5.82 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Sep 30, 2024 | 5.24 Mn |
| Sep 30, 2024 | 5.24 Mn |
| Jun 30, 2024 | 5.91 Mn |
| Jun 30, 2024 | 5.91 Mn |
| Mar 31, 2024 | 4.01 Mn |
| Mar 31, 2024 | 4.01 Mn |